CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results